Latest Atrophic vaginitis Stories
New Campaign FindingtheWords.com Increases Awareness About Painful Intercourse Due to Menopause and Encourages Women to Speak Up to Their Doctors (PRWEB) June
This June, a new commercial for Bescot Healthcare Canada produced by television agency Creative Bube Tube will begin advertising Zestica Moisture: a natural feel, non-hormonal personal hydrogel
RED BANK, N.J., Aug. 17, 2011 /PRNewswire/ -- A new HealthyWomen survey of postmenopausal women reveals that many of them are embarrassed to discuss the vaginal and sexual symptoms of menopause with their health care professional and with their partner.
LONDON, October 7, 2010 /PRNewswire/ -- To mark World Menopause Day on 18th October 2010, the International Menopause Society (IMS) is launching new Recommendations for the management of postmenopausal vaginal atrophy, a distressing condition that will affect up to half of women after menopause. This new guidance is essential as, according to new research, one in two women with vaginal atrophy (VA) will live with their condition unnecessarily for over three years, despite effective...
PRINCETON, N.J., Aug. 23 /PRNewswire-FirstCall/ -- Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market VagifemÂ® (estradiol vaginal tablets) 10 mcg.
PRINCETON, N.J., May 20 /PRNewswire/ -- Novo Nordisk Inc.
PRINCETON, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Novo Nordisk said today that the U.S.
ANN ARBOR, Mich., Sept.
ANN ARBOR, Mich., July 29 /PRNewswire/ -- QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive top-line efficacy results from the first of two patient cohorts in its second pivotal Phase 3 trial of the investigational compound, Ophena(TM) (ospemifene tablets), for the treatment of postmenopausal vulvovaginal atrophy (VVA).
ANN ARBOR, Mich., March 31 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company, today announced that it has completed enrollment in the Company's second pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene tablets).
- The parings of haberdine; also, any kind of fragments.